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Background: Common variable immune deficiency is the most frequently encountered immunodeficiency in adults,
which is characterized by low levels of serum immunoglobulins. Common variable immune deficiency can present
with inflammatory bowel disease-like colitis because of the dysregulated immune system; paradoxically activated T cell
receptor pathways are thought to be pivotal in pathogenesis of common variable immune deficiency-related colitis.
Treatment for severe complications, such as gastrointestinal bleeding, is not established. We report a case of common
variable immune deficiency-related Crohn’s-like disease presenting massive melena, which was successfully treated by
short course infliximab therapy.
Case presentation: A 26-year-old Japanese man with history of common variable immune deficiency presented with
diarrhea, abdominal pain, and fever. Venous administration of antibiotics did not improve his symptoms. Colonoscopy
revealed multiple longitudinal ulcers as well as cobblestone-like change in the ileum end and the ascending colon.
Histopathological examination of biopsy specimen showed erosion and infiltration of T lymphocytes with lack of
B cells. Intravenous hyperalimentation, mesalazine, and steroid did not improve the symptoms and the patient
subsequently presented with massive melena. Colonoscopy revealed a protuberant vessel on one of the ulcers in
the ascending colon. Endoscopic clipping was repeatedly performed for hemostasis, which was only temporarily
successful. In an attempt to manage the bleeding and colitis, a trial of infliximab was given on week 0, week 2
and week 6. Gastrointestinal hemorrhage from the ulcer halted immediately after the first infliximab injection.
Colonoscopy performed after the third infliximab showed remarkable improvement in the ileocolitis. No evidence
of increased susceptibility to infections was observed and the patient has been in clinical remission for 3 years.
Conclusions: We present this case together with review of literature to share our experience of encountering
common variable immune deficiency complicating severe Crohn’s-like disease and to support that infliximab is a
safe and effective treatment that can promptly manage life-threatening intestinal hemorrhage in common variable
immune deficiency-related colitis.
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Common variable immunodeficiency (CVID) is one of
the most frequent symptomatic primary immunodefi-
ciency encountered in adults, and is characterized by
low level of immunoglobulin (Ig) G, IgM, IgA and lack
of B lymphocytes, and some T-cell defects [1-3]. Delay
in diagnosis and treatment of CVID can lead to serious
infections and possible death. The incidence of CVID is
considered to be from 1:50,000 to 200,000 [4]. CVID
usually has a complex and heterogeneous genetic basis,
and the known monogenic CVID defects can explain
only a small group of patients [5].
Since gut is the largest lymphoid organ in the body
which contains the majority of lymphocytes and produ-
cing immunoglobulin, malfunction of the regulatory
mechanisms maintaining the balance between active im-
munity and tolerance in the gastrointestinal tract can
lead to mucosal inflammation. Indeed, gastrointestinal dis-
orders are relatively common manifestations and often the
initial presenting symptom in patients with immune dys-
functions and are observed up to 60% of the patients with
primary immunodeficiency including CVID [2]. Neverthe-
less, incidence of inflammatory bowel disease (IBD)-like
colitis is reported to be as low as 2–4% in these patients
[6]. Tumor necrosis factor alpha (TNF-α) inhibitors in-
cluding infliximab have shown significant effects in classic
IBD, while there is a concern that these treatments can be
accompanied by an increased vulnerability to infections in
CVID patients [3,7]. Although beneficial use of anti-TNF
alpha agents has been reported in a few patients with
Crohn’s-like disease in immunodeficiency to date [3,6],Figure 1 Colonoscopy images of Crohn’s-like disease. Colonoscopy on
Cobblestone change of the mucosa in the ileum end (a) and deep ulceratit is unclear whether they can also improve acute com-
plications such as gastrointestinal hemorrhage. Here, we
report a case of Crohn’s-like disease in CVID leading to
challenging intestinal bleeding, which was successfully
controlled by infliximab.
Case presentation
A 26-year-old Japanese man complaining of diarrhea,
abdominal pain, and fever, was transferred to our hos-
pital after treatment with oral antibiotics had failed.
Three years prior to this admission, the patient was
diagnosed with CVID and had been receiving monthly
intravenous immunoglobulin infusions. He also had a
history of treatment for tuberculosis and repeated pneu-
monia. The patient had not been on non-steroidal anti-
inflammatory drugs (NSAIDs), proton pump inhibitor
(PPI), or other medications that can lead to intestinal
inflammation. Physical examination showed tachycardia
and abdominal tenderness. Laboratory data were the
following; hemoglobin (Hb) 12.0 g/dL (normal: 11.3-
14.9 g/dL), white blood cell count 9000 /μL (4000–
9500 /μL), platelet count 29.1 × 104 /μL (11.0-40.0 × 104 /μL),
serum albumin 3.1 g/dL (4–5 g/dL), serum IgG 229 mg/dL
(870–1700 mg/dL), serum IgA, <24 mg/dL (110–
410 mg/dL), and serum IgM, <18.6 mg/dL (33–190 mg/dL).
Colonoscopy revealed multiple longitudinal ulcers in
the ileum end and the ascending colon (Figure 1a-b).
Cobblestone change of the mucosa of the terminal
ileum was also observed (Figure 1a). No abnormality
was found in the rectum and anus. Pathology examination
showed erosion, distortion of crypts, and infiltration ofonset of diarrhea demonstrating multiple longitudinal ulcers and
ions in the ascending colon (b).
Figure 2 Pathological images of Crohn’s-like disease. Pathological examination of the ascending colon showing crypt distortion, infiltration of
inflammatory cells including T cells, and lack of B cells in the mucosa.
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Most of the inflammatory cells in the intestinal mucosa
were cluster of differentiation (CD) 3+ T cells, whereas CD
20+ B cells were not observed (Figure 2). Cytomegalovirus
was serologically and pathologically negative. Taken to-
gether, we concluded that these findings were consistent
with Crohn’s disease. After admission, he was given mesa-
lazine and intravenous hyperalimentation, which did not
improve his symptoms. Oral administration of 50 mgFigure 3 Colonoscopic clipping of an exposed blood vessel. Emergenc
liner ulcer in the ascending colon (a). Clipping was performed (b).prednisone was given with very limited success. A month
after admission, he had a massive melena and his
hemoglobin fell to 5.5 mg/dL. Colonoscopy demonstrated
an exposed blood vessel in one of the ulcers in the
ascending colon, which was considered to as a potential
bleeding point (Figure 3a). Although hemostasis was tem-
porarily achieved by colonoscopic clipping (Figure 3b), he
repeatedly experienced melena. He underwent emergency
colonoscopy and blood infusion several times in shorty colonoscopy showing an exposed blood vessel on the edge of a
Figure 4 Marked improvement of Crohn’s-like disease after infliximab therapy. Follow-up colonoscopy showing healing of ulcers in the
ileum end (a) as well as marked improvement on lesions in the ascending colon (b).
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infectious diseases by repeated fecal cultures, chest-
abdominal computed tomography, and tuberculosis
tests, infliximab was introduced under careful monitor-
ing; venous injection of 250 mg infliximab was given on
week 0, week 2 and week 6. Gastrointestinal bleeding
from the ulcer halted after the first infliximab injection.
Remarkable improvement was seen after the third
infliximab injection; he was in clinical remission andFigure 5 Improvement of pathological findings after infliximab thera
healing and reduced infiltration of CD3+ T cells.deep ulcers in the terminal ileum had healed. Only
small erosions in the ascending colon were present on
follow-up colonoscopy (Figure 4a-b). Pathological find-
ings also showed improvement with reduced infiltration
of CD3+ T cells (Figure 5). Given his history of tuber-
culosis and repeated infections due to underlying
CVID, we decided to terminate the infliximab therapy.
He was discharged without side effects and has been in
clinical remission for 3 years.py. Pathological examination of the ascending colon showing mucosal
Table 1 Baseline characteristics of four patients with common variable immunodeficiency (CVID) complicating
Crohn’s-like colitis treated with anti-TNF alpha antibodies
Case# Report Age Sex Location of
the lesion
Colonoscopy finding Pathological findings Previous steroid
treatment (outcome)
1 Nos et al. [3] 20 M Ileum, rectum, anus Ulcers Not described Yes (unsuccessful)
2 Nos et al. [3] 24 M Ileum, colon Not described Not described No





4 Current case 26 M Ileum, colon Deep ulcers, cobble
stone-like appearance
Crypt. distortion infiltration
of T lymphocytes depletion
of plasma cells,
Yes (unsuccessful)
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Dysfunction of the regulatory systems maintaining the
balance between active immunity and tolerance in the
gastrointestinal tract can result in mucosal inflammation.
Thus, not surprisingly, CVID displays a wide spectrum of
patterns including infectious colitis, lymphocytic colitis,
collagenous enteritis, celiac diseases, and IBD-like colitis
[2,8-10]. These conditions may be induced via auto-
immunity and altered immune response towards the bac-
terial flora, although the precise mechanisms are yet to
be determined [5]. Several diseases with immunodefi-
ciency including CVID are associated with Crohn’s
disease-like intestinal inflammation; Resnick et al. re-
ported that in 473 patients with CVID followed over 4
decades, 20 (4.2%) developed IBD-like colitis [11]. Dis-
tinguishing IBD from infectious disease, especially in
CVID patients, can be challenging since there is a high
prevalence of infections enterocolitis in these patients
and they both can show the same symptoms [2].
Crohn’s-like disease is generally diagnosed years after
the diagnosis of CVID, but in some cases, colitis can be
found before underlying immunodeficiency is discov-
ered [8]. As observed in classic Crohn’s disease, CVID-
related colitis can present with diarrhea, abdominal
pain, and fever with endoscopic findings of longitudinal
ulcers and cobble stone appearance that preferentially
occurs in proximity to the ileum end. Pathology tests can
show infiltrating inflammatory cells including T cells and
granulomas as well as lack of plasma cells in majority of
the patients [8,12]. Previous reports suggest that lack of
immunoglobulin production may not directly participateTable 2 Details and Outcomes of the patients treated with an
Case# Anti-TNF alpha Duration of anti-TNF* alpha therapy Combin
1 Infliximab 1 year (discontinued)
2 Adalibmab More than 1 year (discontinued)
3 Infliximab Several weeks (continued)
4 Infliximab 4 weeks (discontinued)
*TNF: tumor nerosis factor.in pathogenesis of CVID-related enterocolitis; an
evidence to support this theory is that immunoglobulin
supplementation does not improve the gastrointestinal
symptoms. Rather, abnormal cytokine production through
a T-cell receptor-mediated pathway more likely one of the
key players that contribute to mucosal inflammation [2,8].
In fact, T cell aggregates are observed in the mucosa of the
small intestine in approximately half of CVID patients [8].
Interestingly, a subgroup of CVID even has increased pro-
duction of tumor necrosis factor; a cytokine that is known
to play a significant role in pathogenesis of IBD [13].
Nevertheless, heterogenic features of CVID suggest that
multiple rather than singular pathways may be involved in
intestinal inflammation [2], and it is difficult to completely
rule out the possibility that our patient incidentally had
genetic or environmental background that could cause
classic Crohn’s disease.
It has been described that treatment of Crohn’s-like dis-
ease in CVID patients is similar to the patients with classic
IBD, including corticosteroids and immunosuppressive
drugs [6]. Use of corticosteroids has been reported to raise
risk of infections whereas immunosuppressive reagents
likely do not compromise immune function to a significant
degree [2,3,6,14]. Treatment with anti-TNFα-antibodies
has been previously reported in 3 cases, which are shown
in Tables 1 and 2 together with the current case [3,6].
There is another case series of CVID-related colitis which
were successfully treated by infliximab [14], but these cases
were not included in the table due to lack of colonoscopic/
histological characteristics of Crohn’s disease. All the pa-
tients were male in their 20s or 30s (Table 1). Three casesti-TNF alpha antibodies
ed azathoprine Side effects Response to anti-TNF alpha therapy
Yes No Remission
Yes No Partial response
Yes No Remission
No No Remission
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ited or no effect before anti-TNF alpha therapy (Table 1).
Three cases were treated with infliximab, and one with
adalibmab (Table 2). In all 4 patients, at least some im-
provement was observed after anti-TNF alpha therapy
without significant side effects (Table 2). In the current
case, infliximab was successful to control the intestinal
bleeding in acute phase, suggesting that similar to classic
Crohn’s disease, anti-TNF alpha therapy can also induce
rapid effect to control severe symptoms in CVID-related
colitis. Furthermore, we note that only 3 courses of inflixi-
mab injection were effective enough to maintain 3 years of
remission. In classic Crohn’s disease, main safety problem
with the infliximab administration is formation of anti-
bodies to infliximab, leading to loss of response and infu-
sion reactions (especially when injected after discontinuing
for some period) [15]. However, these issues may be less of
a concern in CVID patients because of their disability to
produce antibody. Further accumulation of the cases is re-
quired to determine if it is beneficial to continue anti-TNF
alpha antibodies after remission in these patients. Another
question would be whether immunosuppressive reagents
such as azathioprine should be added in these patients.
In our case, azathioprine was not considered because
infliximab per se was sufficient to control the colitis. In
other 3 cases, azathioprine has been used together with
anti-TNF alpha treatment (Table 2). Since CVID is a
disease with variability, they may respond to the treat-
ment differently thus each case may as well be evaluated
for need of supplementary treatments in combination with
anti-TNF alpha antibodies. Although previous reports as
well as our case did not show significant infection due to
anti-TNF alpha therapy in CVID patients (Table 2), they
should be carefully monitored for fungal infections, and
injection of immunoglobulin is crucial to avoid severe
complications.Conclusion
In conclusion, we experienced a case of massive intestinal
bleeding due to Crohn’s-like disease in CVID, which
promptly responded to short course infliximab and lead
to mucosal healing. To our knowledge, this is the first
case to show that infliximab is a useful therapy that can
manage this acute and life threatening complication of
CVID-related enterocolitis.Consent
Written informed consent was obtained from the patient
for publication of this Case Report and any accompany-
ing images in agreement with the Helsinki Declaration.
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